Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: A randomized trial

Human Reproduction

Volumn 20, Issue 6, 2005, Pages 1521-1528

  Kilicdag, Esra Bulgan ^a   Bagis, Tayfun ^a   Tarim, Ebru ^a   Aslan, Erdogan ^a   Erkanli, Serkan ^a   Simsek, Erhan ^a   Haydardedeoglu, Bulent ^a   Kuscu, Esra ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

B group vitamin; Folic acid; Hyperhomocysteinaemia; Metformin; PCOS

Indexed keywords

APIKOBAL; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CALCIUM; CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; FOLIC PLUS; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PYRIDOXINE; THIAMINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; VITAMIN B GROUP; VITAMIN D;

AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FATIGUE; FEMALE; FOLIC ACID BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDICAL DOCUMENTATION; NAUSEA AND VOMITING; NONBIOLOGICAL MODEL; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; VITAMIN BLOOD LEVEL;

EID: 20744435927     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh825     Document Type: Article

References (70)

1. Aarsand AK and Carlsen SM (1998) Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 244,169-174.
2. Adams J, Polson DW and Franks S (1986) Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 293,355-359.
3. Arnadottir M, Brattström L, Simonsen O, Thysell H, Hultberg B, Andersson A and Nilsson-Ehle P (1993) The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40,236-240.
4. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S and Escobar-Morreale HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85,2434-2438.
5. Audelin MC and Genest J Jr (2001) Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159,497-511.
6. Boushey CJ, Beresford SA, Omenn GS and Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J Am Med Assoc 274,1049-1057.
7. Brattström LE, Israelsson B, Jeppsson JO and Hultberg BL (1988) Folic acid an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48,215-221.
8. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B and Hamfelt A (1990) Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81,51-60.
9. Brouwer IA (2000) Folic acid, folate and homocysteine: human intervention studies. Eur J Obstet Gynecol Reprod Biol 92,183-184.
10. Carlsen SM, Folling I, Grill V, Bjerve KS, Schneede J and Refsum H (1997) Metformin increases total serum homocysteine levels in nondiabetic male patients with coronary heart disease. Scand J Clin Lab Invest 57,521-527.
11. Caspary WF, Zavada I, Reimold W, Deuticke U, Emrich D and Willms B (1977) Alteration of bile acid metabolism and vitamin-B12-absorbsion in diabetics on biguanides. Diabetologia 13,187-193.
12. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, 2nd and Fitzpatrick LA (2003) Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88,2562-2568.
13. Conway GS, Agrawall R, Betteridge DJ and Jacobs HS (1992) Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 37,119-125.
14. Czeizel AE and Dudas I (1992) Prevention of first occurrence of neural-tube defects by periconceptional vitamin supplementation. New Engl J Med 327,1832-1835.
15. de la Calle M, Usandizaga R, Sancha M, Magdaleno F, Herranz A and Cabrillo E (2003) Homocysteine, folic acid and B-group vitamins in obstetrics and gynaecology. Eur J Obstet Gynecol Reprod Biol 107,125-134.
16. Desouza C, Keebler M, McNamara DB and Fonseca V (2002) Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 62, 605-616.
17. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr Rev 18,774-800.
18. Eskes TK (1998) Open or closed? A world of difference: a history of homocysteine research. Nutr Rev 56,236-244.
19. Fonseca V, Dicker-Brown A, Ranganathan S, Song W, Barnard RJ, Fink L and Kern PA (2000) Effects of a high-fat-sucrose diet on enzymes in homocysteine metabolism in the rat. Metabolism 49,736-741.
20. Guzick DS (1996) Cardiovascular risk in women with polycystic ovarian syndrome. Semin Reprod Endocrinol 14,45-49.
21. Holte J, Gennarelli G, Berne C, Bergh T and Lithell H (1996) Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum. Reprod 11,23-28.
22. Homburg R (2002) What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 17,2495-2499.
23. Homocysteine Studies Collaboration (2002) Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 288,2015-2022.
24. Hoogeveen EK, Kostense PJ, Jakobs C, Bouter LM, Heine RJ and Stehouwer CD (1997) Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 242,389-394.
25. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ and Stehouwer CD (1998) Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arteriscler Thromb Vasc Biol 18,133-138.
26. Jacobsen DW (1998) Homocysteine and vitamins in cardiovascular disease. Clin Chem 44,1833-1843.
27. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B and Erkanli S (2005) Homocysteine levels in women with PCOS treated with metformin versus rosiglitazone: a randomized study. Hum Reprod (in press).
28. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR and Azziz R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83,3078-3082.
29. Lakhani K, Hardiman P and Seifalian AM (2004) Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175,353-359.
30. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A and Brattström L (1995) Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 237,381-388.
31. Leeda M, Riyazi N, De Vries JL, Jakobs C, van Geijn H and Dekker G (1998) Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. Am J Obstet Gynecol 179,135-139.
32. Legro RS, Kunselman AR and Dunaif A (2001) Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111, 607-613.
33. Loverro G (2004) Polycystic ovary syndrome and cardiovascular disease. Minerva Endocrinol 29,129-138.
34. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G and Selvaggi L (2002) The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 53,157-162.
35. Matthews DR, Hosker JP, Rudenski AS, Naylar BA, Treacher DF and Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28,412-419.
36. McCarty MF (2000) Insulin secretion as a potential determinant of homocysteine levels. Med Hypotheses 55,454-455.
37. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG and Scott JM {995) Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 345,149-151.
38. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH, Bromberg IL, Cerone R et al. (1985) The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 37,1-31.
39. Nelen WL, van der Molen EF, Blom HJ, Heil SG, Steegers EA and Eskes TK (1997) Recurrent early pregnancy loss and genetic-related disturbances in folate and homocysteine metabolism. Br J Hosp Med 58,511-513.
40. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Thomas CM and Eskes TK (2000) Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet Gynecol 95,519-524.
41. Orio F, Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, Labella D, Russo T, Zullo F and G (2003) Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88,673-679.
42. Orio F, Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G and Colao A (2004) The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89,3696-3701.
43. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH and Jacobs HS (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51,581-586.
44. 12 and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. J Med Assoc Thai 87,780-787.
45. Powell KE, Thompson PD, Caspersen CJ and Kendrick JS (1987) Physical activity and the incidence of coronary artery disease. Annu Rev Publ Hlth 8,253-287.
46. Rajkhowa M, Bichnell J, Jones M and Clayton RN (1994) Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia. Fertil Steril 61,605-612.
47. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse EW and Prelevic GM (2002) Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87,4496-4501.
48. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19,41-47.
49. Sampson M, Kong C, Patel A, Unwin R and Jacobs HS (1996) Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 45,623-629.
50. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O and Ron-El R (2003) Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18,721-727.
51. Seli E and Duleba AJ (2002) Should patients with polycystic ovarian syndrome be treated with metformin? Proven and potential benefits. Hum Reprod 17,2230-2236.
52. Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA and Tucker MJ (2001) Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynaecol Res 27,163-168.
53. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Walker S, Schorah CJ and Wild J (1983) Further experience of vitamin supplementation for neural tube defect recurrences. Lancet 1, 1027-1031.
54. Splaver A, Lamas GA and Hennekens CH (2004) Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 148,34-40.
55. Stadtmauer LA, Wong BC and Oehninger S (2002) Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome - beyond ovulation induction. Hum Reprod 17,3016-3026.
56. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T and Engberg RA (1998) Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51,415-422.
57. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE and Kuller LH (2000) Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20,2414-2421.
58. Talbott EO, Zborowski JU, Rager JR, Boudreaux MY, Edmundowicz DA and Guzick DS (2004) Evidence for an association between metabolic cardiovascular syndrome and coronory and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinal Metab. 89,5454-5461.
59. Tomkin GH, Hadden DR, Weaver JA and Montgomery DA (1971) Vitamin-B12 status of patients on long-term metformin therapy. Br Med J 2, 685-687.
60. Ubbink JB, van der Merwe A, Vermaak WJH and Delport R (1993) Hyperhomocysteinaemia and the response to vitamin supplementation. Clin Invest 71,993-998.
61. Vrbikova J, Bicikova M, Tallova J, Hill M and Starka L (2002) Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 110,74-76.
62. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R and Belchetz PE (2004) Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clin Endocrinol (Oxf) 60,560-567.
63. Wild RA (2002a) Polycystic ovary synndrome: a risk for coronary artery disease? Am J Obstet Gynecol 186,35-43.
64. Wild RA (2002b) Long-term health consequences of PCOS. Hum Reprod Update 8,231-241.
65. Wild RA, Painter PC, Coulson PB, Carruth KB and Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 61,946-951.
66. Woodside JV, Yarnell JW, McMaster D, Young IS, Harmon DL, McCrum EE, Patterson CC, Gey KF, Whitehead AS and Evans A (1998) Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 67,858-866.
67. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ and Stehouwer CD (2003) Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 254,455-463.
68. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM and Naughten ER (2001) Vascular outcome in patients with homocystinuria due to cystathionine, beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol 21,2080-2085.
69. Yarali H, Yildirir A, Aybar F, Kabakçi G, Bükülmez O, Akgül E and Oto A (2001) Diastolic dysfunction and increased serum homocysteine, concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76,511-516.
70. Zimmermann S, Phillips RA, Dunaif A, Finegood DT, Wilkenfeld C, Ardeljan M, Gorlin R and Krakoff LR (1992) Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 75,508-513.